Phase III bioequivalence trial of ondansetron sublingual spray versus ondansetron sublingual tablet (Zofran®).

Trial Profile

Phase III bioequivalence trial of ondansetron sublingual spray versus ondansetron sublingual tablet (Zofran®).

Planning
Phase of Trial: Phase III

Latest Information Update: 03 Dec 2014

At a glance

  • Drugs Ondansetron (Primary) ; Ondansetron
  • Indications Nausea and vomiting
  • Focus Pharmacokinetics; Registrational
  • Sponsors INSYS Therapeutics, Inc
  • Most Recent Events

    • 03 Dec 2014 New trial record
    • 11 Nov 2014 Insys Therapeutics plans to initiate this pivotal trial in 2015, according to a company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top